USFDA completes inspection of Laurus Labs’ facilities
DSIJ Intelligence / 19 Aug 2017
Laurus Labs has announced that the US Food and Drug Administration (USFDA) has completed the inspection of its API facilities in Units 1 and 3 at Parawada, Visakhapatnam, Andhra Pradesh with two observations that are only procedural in nature.
A leading research and development pharmaceutical company, Laurus Labs has announced that the US Food and Drug Administration (USFDA) has completed the inspection of its API facilities in Units 1 and 3 at Parawada, Visakhapatnam, Andhra Pradesh with two observations that are only procedural in nature. On Friday, the stock closed lower by 1.66% at Rs 536 per share on the BSE. It stock attracted total traded volume of 29,423 shares and traded value of Rs 158.50 lakhs on the NSE.
The company is a manufacturer of active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas. Its business units include Laurus Generics API, Laurus Generics FDF, Laurus Ingredients and Laurus Synthesis. The company’s products include Bis-desmethoxycurcumin, Caffeic Acid, Caffeic Acid Phenylethyl Ester (CAPE), Curcumin, Curcuminoids, Diindolylmethane (DIM), Ferulic Acid, Luteolin, Nobiletin, and .
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.